Lunsumio Market Report 2026

Lunsumio Market Overview

• The Lunsumio market growth in the historic period has been driven by increasing prevalence of non-hodgkin lymphoma, limited treatment options for relapsed follicular lymphoma • Market expansion is supported by expansion of personalized cancer treatment approaches, growing adoption of immuno-oncology combinations • Growth Driver: Increasing Prevalence Of Blood Cancer Drives Growth In The Market • Market Trend: Growing Focus On Fixed-Duration Bispecific Antibody Therapies Through New Product Launches • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Lunsumio Market?

Lunsumio (mosunetuzumab) is a bispecific antibody to treat relapsed or refractory follicular lymphoma. It targets CD20 on B-cells and CD3 on T-cells, aiming to enhance immune system activity against cancer cells. It is approved for patients who have failed prior therapies, offering a novel approach to cancer immunotherapy. The main formulations of lunsumio are injectable formulation (intravenous) and pre-filled syringes. Injectable formulations in the intravenous (IV) form are drugs prepared for direct administration into the bloodstream. IV formulations of lunsumio provide precise dosing and are used for patients who need immediate therapeutic effects. This type of formulation is preferred in clinical settings, particularly for patients with severe conditions. It is indicated for the treatment of relapsed or refractory follicular lymphoma (FL) and other non-Hodgkin lymphomas. It is distributed through direct sales, wholesalers, distributors, retail pharmacies, and online pharmacies, and is utilized by end users in hospitals, oncology clinics, specialty pharmacies, and research institutions.

What Is The Lunsumio Market Growth Forecast?

The growth in the forecast period can be attributed to expansion of personalized cancer treatment approaches, growing adoption of immuno-oncology combinations, increasing investments in oncology biologics, rising demand for outpatient cancer therapies, continued innovation in bispecific antibody platforms. Major trends in the forecast period include increasing adoption of bispecific antibody therapies, rising focus on t-cell engaging immunotherapies, growing use of precision oncology treatments, expansion of targeted therapies for relapsed lymphomas, enhanced integration of biomarker-based patient selection.

Global Lunsumio Market Segmentation

1) By Formulation: Injectable Formulation (Intravenous), Pre-Filled Syringes 2) By Indication: Treatment Of Relapsed Or Refractory FL, Treatment Of Other Non-Hodgkin Lymphomas 3) By Patient Demographics: Adult Patients, Geriatric Patients, Patients With High-Risk Disease Profiles 4) By Distribution Channel: Direct Sales, Wholesalers And Distributors, Retail Pharmacies, Online Pharmacies 5) By End User: Hospitals, Oncology Clinics, Specialty Pharmacies, Research Institutions

What Is The Driver Of The Lunsumio Market?

The increasing prevalence of blood cancer is expected to propel the growth of the lunsumio market going forward. Blood cancer refers to cancers that affect the production and function of blood cells, typically originating in the bone marrow or lymphatic system. The most common types include leukemia, lymphoma, and myeloma. The increasing prevalence of blood cancer can be attributed to factors such as an aging population, genetic predisposition, environmental exposures, weakened immune systems, lifestyle choices, and advancements in diagnostic techniques. Lunsumio (mosunetuzumab) is a bispecific antibody that helps treat blood cancers such as lymphoma by targeting and binding to both cancerous B cells and T cells, enabling the immune system to destroy the cancer cells. It is effective in managing diseases with high blood cancer prevalence, offering a treatment option for patients with relapsed or refractory conditions. For instance, in 2024, according to the American Cancer Society, a US-based non-profit cancer advocacy organization, the number of leukemia cases increased to 62,770, reflecting an increase from 59,610 recorded in 2023. Therefore, the increasing prevalence of blood cancer is driving the growth of the lunsumio industry.

Key Players In The Global Lunsumio Market

Major companies operating in the lunsumio market are Roche Holding AG

Global Lunsumio Market Trends and Insights

A key trend in the Lunsumio market involves advancing innovative approaches, including fixed-duration bispecific antibody therapies, to enhance treatment effectiveness and broaden patient access. Fixed-duration bispecific antibody therapies refer to treatments that use dual-targeting antibodies administered for a set, limited period rather than continuous dosing, enabling effective disease control while reducing long-term treatment burden. For instance, in March 2025, Chugai Pharmaceutical, a Japan‑based oncology/biotech company, launched LUNSUMIO for Intravenous Infusion (mosunetuzumab) for relapsed or refractory follicular lymphoma. The therapy is administered as monotherapy in patients who have failed two or more prior treatments, uses a predetermined treatment duration rather than indefinite therapy to reduce long‑term treatment burden, and is designed to achieve high complete response rates and potentially durable remission in a difficult‑to‑treat patient population..

What Are Latest Mergers And Acquisitions In The Lunsumio Market?

In October 2024, Lonza Group AG, a Switzerland-based manufacturing company that supplies pharmaceutical, healthcare, and life science products, acquired the Genentech manufacturing facility from Roche for $1.2 billion. With this acquisition, Lonza Group AG aims to expand its production capacity, enhance its technological capabilities, and strengthen its position as a leading provider of contract development and manufacturing services for the biopharmaceutical industry. Roche Holding AG is a Switzerland-based pharmaceutical company that developed Lunsumio (mosunetuzumab) to treat relapsed or refractory follicular lymphoma.

Regional Insights

North America was the largest region in the lunsumio market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

What Defines the Lunsumio Market?

The lunsumio market consists of sales of lunsumio (mosunetuzumab) 30 mg/30m, and lunsumio (mosunetuzumab -axgb) 1mh/ml. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Lunsumio Market Report 2026?

The lunsumio market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the lunsumio industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.